Table 3.

Effects of aPL antibodies and control antibodies on renal histology and function

Ab	↑ glomerular deposition/expression			EM	Thrombin generation and renal function			Amelioration of GEC injury and renal failure
	C3	Fibrin	TF	GEC damage	↑TAT	↑BUN	↑ACR	C5aR−/− mice	Low TF mice	Pravastatin
FB1 (C′ activating Ab)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
FC1 (anti-B2GPI Ab)	No	No	No	Yes	Yes	Yes	Yes	No	Yes	Yes
FD1	No	No	No	No	No	No	No	NA	NA	NA
aPL-IgG	Yes	Yes	Yes	No	Yes	Yes	Yes	Partial	Yes	Yes
NH-IgG	No	No	No	No	No	No	No	NA	NA	NA

Effects of FC1, FB1, FD1, aPL-IgG, and NH-IgG on glomerular C3 and fibrin deposition, TF expression and synthesis, plasma thrombin antithrombin III (TAT) levels, and renal function (BUN and ACR). The last 3 columns represent the effect of genetic deletion of C5aR, genetic diminution of TF, and pravastatin treatment on endothelial injury and renal failure.

C′ indicates complement; Ab, antibody; GEC, glomerular endothelial cell; and NA, not applicable.